Requirement for safety monitoring for approved multiple sclerosis therapies: an overview
暂无分享,去创建一个
B. Hemmer | E. Frohman | B. M. Greenberg | U. Zettl | B. Kieseier | O. Stüve | E. Frohman | H. Hartung | P. Rommer | B. Greenberg | T. Menge | P. Rommer
[1] D. Jayne,et al. SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .
[2] Jeffrey A. Cohen,et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.
[3] A. Winkelmann,et al. Multiple sclerosis treatment and infectious issues: update 2013 , 2014, Clinical and experimental immunology.
[4] Linda J. Scarazzini,et al. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] Craig S. Miller,et al. JC virus antibody status underestimates infection rates , 2013, Annals of neurology.
[6] Yasuyuki Kihara,et al. Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy , 2013, Journal of the Neurological Sciences.
[7] M. Sweetser,et al. Manufacturer's response to case reports of PML. , 2013, The New England journal of medicine.
[8] J. Weis,et al. PML in a patient treated with fumaric acid. , 2013, The New England journal of medicine.
[9] F. Barkhof,et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. , 2013, The New England journal of medicine.
[10] J. A. Charles. Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review , 2013, Neurology.
[11] Jeffrey A. Cohen,et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial , 2012, The Lancet.
[12] Christian Confavreux,et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial , 2012, The Lancet.
[13] D. Arnold,et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.
[14] David H. Miller,et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. , 2012, The New England journal of medicine.
[15] Tamara Castillo-Triviño,et al. Hepatitis autoinmune en un paciente con esclerosis múltiple en tratamiento con acetato de glatiramero , 2012 .
[16] T. Vollmer,et al. Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab , 2012, Journal of neuropathology and experimental neurology.
[17] F. Paul,et al. Mitoxantrone Induces Natural Killer Cell Maturation in Patients with Secondary Progressive Multiple Sclerosis , 2012, PloS one.
[18] L. Kappos,et al. Teriflunomide added to interferon-β in relapsing multiple sclerosis , 2012, Neurology.
[19] Meena Subramanyam,et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.
[20] K. Subramaniam,et al. Glatiramer acetate induced hepatotoxicity. , 2012, Current drug safety.
[21] A. Bar-Or,et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years , 2012, Multiple sclerosis.
[22] R. Rhoades,et al. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. , 2012, Current opinion in neurology.
[23] H. Hartung,et al. Vaccination against infection in patients with multiple sclerosis , 2012, Nature Reviews Neurology.
[24] T. Korn,et al. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. , 2012, Clinical immunology.
[25] A. López de Munain,et al. [Autoimmune hepatitis in a patient with multiple sclerosis under treatment with glatiramer acetate]. , 2012, Revista de neurologia.
[26] Christian Confavreux,et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. , 2011, The New England journal of medicine.
[27] Y. Ben-Shlomo,et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort , 2011, Neurology.
[28] Ludwig Kappos,et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring , 2007, The Lancet Neurology.
[29] D. Herr,et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation , 2010, Proceedings of the National Academy of Sciences.
[30] K. Simon,et al. Anti‐JC virus antibodies: Implications for PML Risk Stratification , 2010, Annals of neurology.
[31] H. Neumann,et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. , 2010, Brain : a journal of neurology.
[32] Bernhard Hemmer,et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis , 2010, The Lancet Neurology.
[33] J. Geddes,et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS , 2010, Neurology.
[34] Ludwig Kappos,et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[35] Ludwig Kappos,et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[36] M. Sahraian,et al. Alemtuzumab and multiple sclerosis: therapeutic application. , 2010, Expert opinion on biological therapy.
[37] J. Wolinsky,et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate , 2010, Multiple sclerosis.
[38] S. Dhib-jalbut,et al. Interferon-β mechanisms of action in multiple sclerosis , 2010, Neurology.
[39] D. Solís. US Food and Drug Administration , 2010 .
[40] E. Major,et al. Monoclonal antibodies and progressive multifocal leukoencephalopathy , 2009, mAbs.
[41] M. Filippi,et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study , 2009, The Lancet Neurology.
[42] H. Hartung,et al. INTERFERON BETA TREATMENT DOES NOT INDUCE ORGAN-SPECIFIC AUTOANTIBODIES IN MULTIPLE SCLEROSIS , 2009, Neurology.
[43] B. Sharrack,et al. Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis , 2009, Journal of Neurology.
[44] M. Ban,et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). , 2009, The Journal of clinical investigation.
[45] Hans Lassmann,et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.
[46] K. Selmaj,et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. , 2008, The New England journal of medicine.
[47] M. Atkins,et al. Melanoma complicating treatment with natalizumab for multiple sclerosis. , 2008, The New England journal of medicine.
[48] M. Krumbholz,et al. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. , 2007, Archives of neurology.
[49] S. Youssef,et al. Type II monocytes modulate T cell–mediated central nervous system autoimmune disease , 2007, Nature Medicine.
[50] M. Trojano,et al. Glatiramer acetate in multiple sclerosis: a review. , 2007, CNS drug reviews.
[51] J. De Keyser,et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.
[52] Urso FORTE. Urso. HIGHLIGHTS OF PRESCRIBING INFORMATION , 2007 .
[53] H P Hartung,et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.
[54] R. Scheyer,et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses , 2006, Neurology.
[55] Christian Confavreux,et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[56] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[57] L. Durelli,et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with NAb , 2006, Multiple sclerosis.
[58] H. Hartung,et al. Therapeutic role of mitoxantrone in multiple sclerosis. , 2006, Pharmacology & therapeutics.
[59] M. Sela,et al. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[60] D. Goodin,et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial , 2005, Journal of the Neurological Sciences.
[61] K. Tyler,et al. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.
[62] S. Atlas,et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.
[63] L. Murri,et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. , 2005, The Journal of clinical endocrinology and metabolism.
[64] H. Hartung,et al. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis , 2005, The Lancet Neurology.
[65] M. Rovaris,et al. Glatiramer acetate in multiple sclerosis , 2005, Expert review of neurotherapeutics.
[66] C. Sindic,et al. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone , 2005, Journal of Neurology.
[67] H. Tremlett. Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects , 2005, Neurology.
[68] C. Farina,et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. , 2004, Brain : a journal of neurology.
[69] C. Weiller,et al. Severe heart failure in a young multiple sclerosis patient , 2003, Journal of Neurology.
[70] H. Hartung,et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial , 2002, The Lancet.
[71] D. Goodkin,et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis , 2002, Multiple sclerosis.
[72] Michael D. Davis,et al. The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.
[73] A. Ghezzi,et al. Thyroid function and autoimmunity during interferon β-1b treatment : A multicenter prospective study , 2001 .
[74] Richard A. C. Hughes,et al. PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS , 2001, Neurology.
[75] J. R. Scotti,et al. Available From , 1973 .
[76] J H Simon,et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.
[77] P. Altmeyer,et al. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use , 1999, The British journal of dermatology.
[78] A. Compston,et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis , 1999, Annals of neurology.
[79] H. Lassmann,et al. Lethal capillary leak syndrome after a single administration of interferon beta-1b. , 1999, Neurology.
[80] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[81] J S Wolinsky,et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability , 1998, Neurology.
[82] B. Weinshenker,et al. The Natural History of Multiple Sclerosis: Update 1998 , 1998, Seminars in neurology.
[83] E. Cabanis,et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[84] S. Reingold,et al. Defining the clinical course of multiple sclerosis , 1996, Neurology.
[85] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[86] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[87] Jeffrey A. Cohen,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.
[88] J. Tite,et al. Humanized monoclonal antibody CAMPATH‐1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell‐derived material , 1992, Clinical and experimental immunology.
[89] G. Hale,et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. , 1983, Blood.
[90] A. Meshorer,et al. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide , 1971, European journal of immunology.
[91] W SCHWECKENDIEK,et al. [Treatment of psoriasis vulgaris]. , 1959, Medizinische Monatsschrift.